Tipharco Pharmaceutical Joint Stock Company (DTG) would like to provide an explanation to the Commission, the Exchange, and the Company's shareholders regarding the changes in revenue and profit after tax presented in the reviewed interim financial statements for 2026 compared with the same period in 2025, as follows:
The Company's profit after tax for the first six months of 2026 increased compared with the same period last year, mainly due to the Company's continued implementation of measures to enhance the efficiency of its production and business operations. In particular, raw material procurement was closely managed, contributing to the stabilization of raw material prices and, consequently, better control of production costs.
In addition, the Company adjusted its production and business plan in line with market demand, resulting in higher production output and better control of production costs, thereby improving the gross profit margin and increasing revenue during the period.
Furthermore, since the end of 2025, the Company has continued to closely manage its capital resources and debt structure. As a result, finance costs, primarily interest expenses, decreased compared with the same period last year, contributing to the improvement of the Company's business performance.
The above is the Company's explanation for the changes in its business results for the first six months of 2026 compared with the same period last year. The Company respectfully provides this information to its shareholders, investors, and other relevant stakeholders.
Thank you for your attention.
Attachments: